American Society of Hirudotherapy

Microvascular Free-Flap Head and Neck Reconstruction: The Utility of the Modified Frailty Five-Item Index

Research article published in Journal of reconstructive microsurgery (2024)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical LiteratureOthman et al. · Journal of reconstructive microsurgery, 2025

Abstract

BACKGROUND:  Microvascular free tissue transfer is a common tool for the reconstruction of oncologic head and neck defects. Adequate preoperative assessment can aid in appropriate risk stratification and peri-operative optimization. The modified five-item frailty index (mFI-5) is a validated risk-assessment scale; however, its utility in head and neck free-flap reconstruction is unknown when compared with other common risk factors. METHODS:  A retrospective, single-institution chart review (2017-2020) was performed. Patient demographics, defect and repair characteristics, pre- and peri-operative factors, and flap outcomes were recorded. A high mFI-5 score was defined as greater than 2. The total score, as well as other patient factors, was correlated to postoperative flap complications. RESULTS:  A total of 214 patients were deemed appropriate for conclusion. The mean age was 63.9 ± 12.8 years. There were an even number of males (52.8%) and females (47.2%). A fifth of subjects (20.8%) underwent preoperative radiotherapy. There were 21 cases (9.8%) of complete flap loss. A total of 34 patients (29.4%) experienced any postoperative complication related to flap outcomes. An elevated mFI-5 was significantly associated with a higher overall rate of postoperative complications (39.7 vs. 29.4%, p < 0.019) and total flap loss (16.7% vs. 6.6%, p < 0.033). Preoperative radiation was found to be associated with an increased complication rate (p < 0.003). CONCLUSION:  The mFI-5 score may be a potentially significant tool in the risk stratification of patients undergoing head and neck free-flap reconstruction as opposed to commonly utilized risk factors. Preoperative radiotherapy is significantly associated with postoperative complications. Appropriate preoperative assessment may help tailor patient care preoperatively.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansMaleFemaleFree Tissue FlapsMiddle AgedRetrospective StudiesPlastic Surgery ProceduresHead and Neck NeoplasmsFrailtyPostoperative ComplicationsAgedRisk AssessmentRisk Factors

Summary

In 214 head and neck free-flap patients, an elevated modified five-item frailty index was significantly associated with more postoperative complications (39.7% vs 29.4%) and total flap loss (16.7% vs 6.6%); preoperative radiotherapy also raised complication rates.

Context

This retrospective study evaluated whether the modified five-item frailty index (mFI-5) predicts postoperative complications in 214 patients undergoing microvascular free-flap head and neck reconstruction. An elevated mFI-5 was significantly associated with higher overall complication and total flap loss rates. Free-flap reconstruction is a clinical setting where medicinal leech therapy may be used to manage venous congestion and salvage compromised flaps. However, the abstract does not mention leeches, hirudotherapy, or venous congestion management.

Citation

Reference (Vancouver style)

Othman S, Robinson E, Kamdar D, Pereira L, Miles B, Kasabian A, et al. Microvascular Free-Flap Head and Neck Reconstruction: The Utility of the Modified Frailty Five-Item Index. J Reconstr Microsurg. 2025;41(3):270-276. doi:10.1055/s-0044-1788540. PMID: 39038462

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.